Antibody Drug Conjugate (ADC) Contract Manufacturing

Excellence in very injection 

Time is life, so in the rapidly evolving sterile injectable space, Pfizer's expertise is key to helping you deliver your innovative therapeutic safely and successfully
to the patients who need it.

Global expertise. Specialized ...

Advancing your microbial therapies with expertise, scale and quality 

Microbial therapies face unique challenges, from complex fermentation scale-up to safeguarding long-term supply. With microbial fermentation capacity across the global Pfizer network, we help bring the scale, resilience ...

Making the complex, simple 
Powered by Pfizer's global expertise and a “right-first-time” approach, we help streamline your OSD manufacturing journey – because time is life.

Your complex OSD challenges, expertly handled • Decades of experience in successfully del...

Let's light up your gene and cell therapy together. Our Pfizer scientists and manufacturing experts are here to help you navigate the path to market for your gene and cell therapy Experience is crucial when producing life-changing gene and cell therapies, so choosing the right CDMO is key. At Pfizer, ou...

In this exclusive interview, Jim Donovan, VP and General Manager of Pfizer CentreOne, shares real-world insights on navigating the toughest challenges in ADC and biologics manufacturing: from high-containment conjugation and accelerated tech transfer to supply chain resilience and regulatory readiness.

Pfizer CentreOne Sterile Injectable Brochure

Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.  

Pfizer CentreOne Oral Solid Dose Brochure

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

Pfizer CentreOne _ Antibody Drug Conjugate _  Mini Brochure

Vaccines for RSV from GSK and Pfizer to be analysed by a panel of experts with a view to informing a decision from the US FDA on their approval. 

Pfizer CentreOne_Sterile Injectable _ Collaboration Whitepaper

Partner with creative scientists and problem-solvers dedicated to making your drug development journey a success. 

Pfizer CentreOne_Highly Potent Oral Solide Dosage _ Whitepaper

Pfizer and BioNTech’s shot on Monday became the first COVID-19 vaccine to be granted full approval by the US Food and Drug Administration.

Pfizer CentreOne_Antibody Drug Conjugate _Whitepaper

In this presentation, three of Pfizer CentreOne’s technology transfer MVPs present the playbook for a project accelerated by the pandemic.

The team will discuss the vital moments in the project that enabled success at a pace never seen before, including: The value and need for having all parties (SMEs and decision-makers) at the table at every meeting - killing ‘we’ll get back to you’ time! Optimizing and streamlining engineering runs Better batch strategy Orchestration of effort - the need for effective vendor relationships, responsiveness and everyone knowing their role

For each, we’ll answer:

What did we use to do? What do we do now, why do we do it that way and how does it expedite timelines? All with the ultimate question in mind: how does this benefit patients?


Click here to register

Talk of bringing back domestic manufacturing to North America has dominated conversations around pharma manufacturing for years, and have been a key talking point in government post-pandemic recovery plans, but how far have we come and who is this really working for? Asian CDMO’s recognizing the trend for western domestic production are globalizing their operations. Will there be an increase in the Civica Rx business model? This session broadcast was a part of CPHI North America Show

In this session, originally broadcast as part of the CPHI North America content programme, Pfizer CentreOne’s presenters, Tom Wilson and Nicole Strauss will take a deep dive into the recipe for supply chain management success in the face of capacity challenges. Solving those challenges revolves around trust; building it, nurturing it and utilizing it. In a way, it’s like having all the ingredients to bake the perfect cake. If you are missing a key ingredient, the whole recipe is in jeopardy. Supply chain issues and logistics can feel startlingly similar. Raw materials, schedules, processes and communication are all key elements, any of which can be thrown off track by missing components or information. Tune in now to understand how to optimise supply chain management.

Outsourcing drug manufacturing is a common solution to building manufacturing capacity among drug sponsors. Developing appropriate oversight for CDMO’s is key to a successful product launch. This session will discuss key responsibilities for drug sponsors in overseeing their providers, including which responsibilities can be delegated and when. We will also explore best practices in obtaining optimum performance and adjusting oversight as necessary to reduce overall program risk. This session was broadcast as part of CPHI NA show.

Q&A featuring Raman Sehgal, host of Molecule to Market and Stephanie Watson, Global Strategy and Commercial Planning Lead at Pfizer CentreOne Diving into the biggest challenges the supply chain are currently facing, as well as potential solutions Dissect successful responses and shed light on the future trends we should all be preparing for. This session was broadcast as part of the CPHI North America show.

Where QBD was the orchestral sheet music that determined how drug product development has been harmonized over the last 15 or so years, contemporary patient-centric risk-based approaches to drug development are the pop evolution. The music is still beautiful when produced well - but the focus is no longer on the full orchestra, it's on key players and moments. First - think McCartney and Lennon - one without the other and we don’t have the Beatles. The same can be said for collaboration between drug process development and commercial production colleagues. They are central to ensuring that products are easier to transfer and can be scaled, and that manufacturing challenges are identified early on and addressed proactively. In his keynote, Bernd Schümmelfeder Director-Team Leader PPD Business Development, Pfizer explores how lyrics (communication), rhythm (standardization), bass (structured development processes), and lead guitar (the use of smart technologies) throughout the drug development process come together to create beautiful music - a drug that gets to patients safely and at pace. Key areas for discussion include: Clear decision and inflection points to manage costs and prioritize projects with a higher probability of success Smart technologies like modeling to identify challenges early on and avoid late-stage pitfalls Use of platform technologies to simplify the tech transfer process and improve process robustness Areas to optimize the product development and manufacturing process to make it more efficient, cost-effective, and patient-focused

Pfizer’s manufacturing excellence story can be likened to the sport of crew rowing. Eight people, literally rowing in the same direction in unison. Multiple efforts, focus and strengths are combined in the pursuit of a common goal. It takes precise choreography, teamwork and a common understanding of the manner in which results can and should be achieved.
“The power of the team is unlocked as each rower works in harmony, adding their power to the whole. When everyone buys in and commits to the system, great things can be achieved.”
IMEx (Integrated Manufacturing Excellence) is Pfizer’s production system that mandates a common way of working, applies that at all levels, globally and rewards individuals, teams and facilities on their outcomes. The advantages and success of IMEx are shown clearly in increased speed to patients. That’s the focal point of what Pfizer does and a tool like IMEx is important because it supports that global goal.
But how do we apply it to our CDMO business? How do we leverage such a powerful tool to create the same value for our clients? How does the coxswain and team, working together, create harmony with a supply chain that isn’t entirely our own?
Answering these questions are the crux of this presentation.

Explore Pfizer CentreOne’s capabilities—download our brochure to see how we help advance complex programs with confidence.